Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The pharma world is on tenterhooks, waiting to see how the Inflation Reduction Act will impact drug innovation and pricing, and how the Federal Trade Commission could foil M&A plans. As valid as these concerns are, however, they shouldn't overshadow what is arguably a more pressing issue: the shifting dynamics in the US payer landscape. The…
In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues,…
This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…
Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top…
After a bruising 2021, biotech investors are hoping for a rebound. We interviewed investors and biopharma participants from across the sector, asking them to share their…
Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…
This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape. Access…
The biopharma and medtech sectors have been racing to deliver treatments, vaccines and other solutions to Covid-19 for close to two years now. What progress has been made…
Conducted as a virtual event from 16 to 21 September, ESMO 2021 brought together an international community of experts across disciplines. Once again, this oncology…
The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer. While it took place in virtual format from September 8-14, this…
Special purpose acquisition companies, known as Spacs or “blank check companies”, are not new but have recently rocketed in popularity as a vehicle for going public…